Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programsNov 16Quarterly updateLeonaBioPrelude Therapeutics Incorporated
Prelude reports Q2 2026 results, plans Phase 1 start for KAT6A degrader PRT13722Aug 11Quarterly updatePrelude Therapeutics IncorporatedPRT12396